KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Pacira BioSciences (PCRX) EPS (Weighted Average and Diluted) (2016 - 2026)

Pacira BioSciences has reported EPS (Weighted Average and Diluted) over the past 17 years, most recently at $0.07 for Q1 2026.

  • For Q1 2026, EPS (Weighted Average and Diluted) fell 30.0% year-over-year to $0.07; the TTM value through Mar 2026 reached $0.12, up 105.29%, while the annual FY2025 figure was $0.16, 107.44% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q1 2026 was $0.07 at Pacira BioSciences, up from $0.04 in the prior quarter.
  • Over five years, EPS (Weighted Average and Diluted) peaked at $0.52 in Q4 2023 and troughed at -$3.11 in Q3 2024.
  • A 5-year average of -$0.05 and a median of $0.12 in 2025 define the central range for EPS (Weighted Average and Diluted).
  • Biggest five-year swings in EPS (Weighted Average and Diluted): skyrocketed 1250.0% in 2023 and later tumbled 1452.17% in 2024.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.22 in 2022, then surged by 336.36% to $0.52 in 2023, then crashed by 32.69% to $0.35 in 2024, then tumbled by 88.57% to $0.04 in 2025, then surged by 75.0% to $0.07 in 2026.
  • Business Quant data shows EPS (Weighted Average and Diluted) for PCRX at $0.07 in Q1 2026, $0.04 in Q4 2025, and $0.12 in Q3 2025.